Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/clinchem/hvab001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal imaging evaluation of the inflammatory role of purinergic AA receptors during subacute and chronic ischemic stroke.
J Cereb Blood Flow Metab
September 2025
Achucarro Basque Center for Neuroscience, Leioa, Spain.
Adenosine A receptors (AARs) have shown promising therapeutic properties despite their controversial role in modulating stroke outcome. However, the temporal evolution of cerebral AARs density after cerebral ischemia and its subsequent neuroinflammatory response have been scarcely explored. In this study, the expression of AARs after transient middle cerebral artery occlusion (MCAO) was evaluated in rats by positron emission tomography (PET) with [C]SCH442416 and immunohistochemistry (IHC).
View Article and Find Full Text PDFMetabolic benefits conferred by duplication of the facilitated trehalose transporter in Lepidoptera.
Insect Sci
September 2025
Integrative Science Center of Germplasm Creation in Western China (Chongqing) Science City, Biological Science Research Center, Southwest University, Chongqing, China.
In addition to being one of the primary processes for the formation and expansion of gene families, gene duplication also establishes the basis for the diversity and redundancy of gene functions, providing an abundance of genetic resources and a potent adaptive potential for biological evolution. Trehalose is a high-quality carbon source and blood sugar in insects. However, recent theoretical developments suggest that mechanisms for facilitated trehalose transport in lepidopteran insects remain relatively scarce.
View Article and Find Full Text PDFLymphoma driver mutations at the root of somatic evolution of nerve-damaging autoantibodies in myelin associated glycoprotein neuropathy.
J Autoimmun
September 2025
Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Cellular Genomics Futures Institute & School of Biomedical Sciences, UNSW Sydney, Australia. Electronic address:
Background: In autoimmune disease it is not understood how self-reactive B cells escape immune tolerance checkpoints to produce pathogenic autoantibodies.
Objective: In patients with demyelinating polyneuropathy caused by IgM autoantibodies against myelin associated glycoprotein (MAG) and the sulphated trisaccharide CD57, we aimed to test the hypothesis that B cells making the autoantibody escaped tolerance by acquiring lymphoma driver somatic mutations.
Methods: Deep single-cell RNA, DNA, flow cytometric and antibody specificity analysis of blood from three patients with MAG neuropathy.
Advancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.
Ann Hematol
September 2025
Institute for Workflow-Management in Health Care, European University of Applied Sciences, Cologne, Germany.
In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are either refractory to first-line therapy or relapse within 12 months, chimeric antigen receptor (CAR) T-cell therapy is more effective than salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as second-line therapy. Adoption of CAR T-cell therapy into routine clinical practice involves a period of adaptation and refinement of clinical processes. We aimed to document the evolution of clinical processes for CAR T-cell therapy during 2022 and 2023, and compare healthcare resource utilization (HCRU) associated with CAR T-cell and ASCT processes in routine clinical practice.
View Article and Find Full Text PDFTumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer.
Semin Oncol
September 2025
Departments of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, New Jersey, USA. Electronic address:
Chimeric antigen receptor (CAR) T-cell therapy has changed how we treat blood cancers but hasn't worked as well for solid tumors like pancreatic ductal adenocarcinoma (PDAC), mainly because these tumors are very aggressive and resistant to regular treatments. This review critically examines peer-reviewed studies to chart the evolution of immunotherapy in PDAC, emphasizing the unique barriers to effective CAR T-cell treatment and emerging strategies to overcome them. CAR T-cells that focus on tumor-related markers like mesothelin, HER2, and MUC1 have shown promise in early research models.
View Article and Find Full Text PDF